2025-521754-41-00尚未招募1 期
A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- Immunic AG
- 入组人数
- 24
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Andreas Muehler
Scientific
Immunic AG
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa from 2 manufacturing processes, administered as a single subcutaneous 450 IU dose to pituitary-suppressed healthy premenopausal female participants.Infertility2023-507066-91-00Merck Healthcare KGaA14
已完成
1 期
A Phase I, Single-center, Open-label Fixed-sequence Study to Assess the Effects of PRN1008 on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy AdultsHealthy VolunteersInflammatory and Immune System - Autoimmune diseasesRheumatoid ArthritisACTRN12614001303639Principia Biopharma Australia Pty Ltd12
已完成
1 期
A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin in healthy male participants.2023-509226-21-00Abivax, Abivax24
已完成
不适用
A single-center, open-label, fixed-sequence Phase 1 trial to evaluate the effect of multiple doses of pritelivir on the pharmacokinetics of substrates for CYP2C9, CYP2B6, CYP3A4 and OATP2B1NL-OMON50697AiCuris Anti-infective Cures AG16
已完成
1 期
A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tablet Formulations of Lazertinib2022-502814-99-00Janssen - Cilag International, Janssen - Cilag International72